Testing diuretics to predict kidney disease progression
Diuretic Testing in Chronic Kidney Disease
This study is testing if using diuretics can help predict how quickly chronic kidney disease gets worse in patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 86 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Erasmus Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rotterdam, South Holland) |
| Trial ID | NCT06841692 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to predict the progression of chronic kidney disease (CKD) through diuretic testing in affected patients. Participants will receive diuretics, specifically bumetanide and hydrochlorothiazide, followed by blood and urine collections to assess kidney function. The study will also compare results from CKD patients to healthy individuals to identify differences in kidney response. The primary focus is to determine if poorer diuretic test results correlate with faster progression of CKD.
Who should consider this trial
Good fit: Ideal candidates include individuals with chronic kidney disease stage G3 and healthy participants with normal kidney function.
Not a fit: Patients with known allergies to diuretics, those undergoing systemic chemotherapy, or individuals with severe electrolyte imbalances may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new method for predicting the progression of chronic kidney disease, allowing for earlier interventions.
How similar studies have performed: While the approach of using diuretic testing in CKD is not widely established, similar methodologies have shown promise in assessing kidney function in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for CKD subjects: * CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit Inclusion Criteria for Healthy subjects: • eGFR within the expected range for age (a decline of 1 ml/min/1.73 m2 per year starting from age 40 is considered the normal age-related decline in kidney function Exclusion Criteria: * Known intolerance or allergy to the diuretics * Current systemic chemotherapy for malignancy * Kidney transplant recipient * Use of calcineurin-inhibitors * Life expectancy \< 12 months * Current immunosuppressive treatment for glomerulonephritis * Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team * Hypokalemia or hyperkalemia (K+ \< 3.0mmol/L or K+ \> 5.5 mmol/L) at inclusion visit * Hypo- or hypernatremia (Na+ \< 130 mmol/L or Na+ \> 150mmol/L) at inclusion visit * Inherited tubulopathy as the cause of CKD * Autosomal dominant polycystic or tubulointerstitial kidney disease causing CKD * Clinically relevant heart failure (New York Heart Association class III or IV) * Therapy-resistant hypertension, defined as systolic blood pressure \> 180mmHg at the inclusion visit * Current treatment with inhibitors of Organic anion transporters: probenecid, pravastatin, cimetidine, cephalosporins, acetazolamide \[22\] * Active hepatitis during last outpatient visit * Liver cirrhosis in advanced stage (Child-Pugh B or C) * Active drug- or alcohol abuse * Not being able to tolerate a 28-day washout of one of the drugs interfering with diuretic testing. * Women who are pregnant, breastfeeding, or planning on becoming pregnant before the test day
Where this trial is running
Rotterdam, South Holland
- Erasmus MC — Rotterdam, South Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Ewout J. Hoorn, MD, PhD — Erasmus Medical Center
- Study coordinator: Sebastian B Beckmann, MD
- Email: s.beckmann@erasmusmc.nl
- Phone: +31 6 39022349
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.